Effectiveness and safety of available treatments for COVID-19 during pregnancy: a critical review

Background: COVID-19 is a pandemic disease caused by the SARS-CoV-2 and it spread globally in the last few months. The complete lack of specific treatment forced clinicians to use old drugs, chosen for their efficacy against similar viruses or their in vitro activity. Trials on patients are ongoing but the majority of information comes from small case series and single center reports. We aimed to provide a literature review on the putative effectiveness and safety of available treatments for COVID-19 in pregnant women. Methods: We reviewed all the available literature concerning the drugs that have been used in the treatment of COVID-19 during pregnancy and whose safe assumption during pregnancy had been demonstrated by clinical studies (i.e. including studies on other infectious diseases). Drugs contra-indicated during pregnancy or with unknown adverse effects were not included in our review. Results and conclusions: Clinical trials are not often conducted among pregnant patients for safety reasons and this means that drugs that may be effective in general population cannot be used for pregnant women due to the lack of knowledge of side effects in this category of people.The choice to use a specific drug for COVID-19 in pregnancy should take into account benefits and possible adverse events in each single case. In the current situation of uncertainty and poor knowledge about the management of COVID-19 during pregnancy, this present overview may provide useful information for physicians with practical implications. © 2020, © 2020 Informa UK Limited, trading as Taylor & Francis Group.

Favilli A.1 , Mattei Gentili M. , Raspa F.2 , Giardina I.2 , Parazzini F.3 , Vitagliano A.4 , Borisova A.V. 5 , Gerli S.2
Taylor and Francis Ltd
  • 1 Department of Obstetrics and Gynecology, AOUI Verona, Verona, Italy
  • 2 Department of Surgical and Biochemical Sciences, Centre of Perinatal and Reproductive Medicine, University of Perugia, Perugia, Italy
  • 3 Fondazione IRCCS Cà Granda, Dipartimento Materno-Infantile, Ospedale Maggiore Policlinico, Università degli Studi di Milano, Dipartimento di Scienze Cliniche e di Comunità, Universita' di Milano, Milan, Italy
  • 4 Department of Women’s and Children’s Health, University of Padua, Padova, Italy
  • 5 Department of Obstetrics and Gynecology with the Course of Perinatology, Peoples Friendship University of Russia (RUDN University), Moscow, Russian Federation
Ключевые слова
COVID-19; pregnancy; SARS-CoV-2; therapy
Дата создания
Дата изменения
Постоянная ссылка

Другие записи